220904-99-4

Basic information

• Product Name: -5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one
• Synonyms: -5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one;2H-Indol-2-one, 5-chloro-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-;CID-25014542
• CAS NO: 220904-99-4
• Molecular Formula: C₁₅H₈Br₂ClNO₂
• Molecular Weight: 429.49052
• EINECS: -0
• Mol File: 220904-99-4.mol

Chemical Properties

• Boiling Point: 535.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.938±0.06 g/cm3(Predicted)
• PKA: 5.84±0.25(Predicted)
• CAS DataBase Reference: -5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: -5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one(220904-99-4)
• EPA Substance Registry System: -5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one(220904-99-4)

Safety Data

• Hazardous Substances Data: 220904-99-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
-5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one is used as a pharmaceutical agent for its antioxidant properties, which can help in combating oxidative stress-related diseases and conditions. Its ability to neutralize free radicals and protect cells from oxidative damage makes it a valuable asset in the development of therapeutics aimed at improving health outcomes.
-5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one is also utilized as an antimicrobial agent, given its capacity to inhibit the growth of various microorganisms. This characteristic is particularly beneficial in the creation of new antibiotics to address the growing issue of antibiotic resistance and in the development of antiseptic and disinfectant products.
Furthermore, -5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one is employed as an anticancer agent, leveraging its potential to interfere with the growth and proliferation of cancer cells. Its application in oncology research and drug development could lead to the discovery of novel treatments for various types of cancer, enhancing patient outcomes and survival rates.
In Drug Discovery:
-5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one is used as a lead compound in drug discovery, where its unique molecular structure and biological activities are investigated for the development of new pharmaceuticals. -5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indolin-2-one's multifaceted properties make it an attractive candidate for research aimed at identifying and optimizing potential therapeutic agents.
While the provided materials do not specify different applications across various industries, the potential uses outlined above are based on the compound's inherent properties and the common applications of similar compounds in the pharmaceutical and medicinal chemistry fields. Further research and development would be necessary to fully realize the compound's potential and to tailor its applications to specific therapeutic areas or industrial needs.

Upstream product

• 17630-75-0 5-chloro-indolin-2-one 
• 2973-77-5 3,5-dibromo-4-hydroxybenzaldehyde 

Relevant articles and documents

Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond

The most prevalent leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is associated with Parkinson's disease (PD). It enhances kinase activity and has been identified in both familial and sporadic cases. Kinase activity was reported to be required for LRRK2 mutants to exert their toxic effects. Hence LRRK2 kinase inhibition may be a promising therapeutic target for PD. Here we report on the discovery and characterization of indolinone based LRRK2 inhibitors. Indolinone 15b, the most potent and selective inhibitor of the present series, is characterized by an IC50of 15 nM against wild-type LRRK2 and 10 nM against the LRRK2 G2019S mutant, respectively. Compound 15b was further evaluated in a kinase panel including 46 human protein kinases and in a zebrafish embryo phenotype assay, which enabled toxicity determination in whole organisms.

Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3

The inhibition of FLT-3 activity is an interesting target for the treatment of acute myeloid leukemia (AML). The serendipitous identification of FLT-3 inhibitors from a CK1/γ-secretase programme provided compounds with dual inhibitory activity. We analyzed the structure-activity relationship of these inhibitors and derivatized them to arrive at compounds with reduced impact on γ-secretase activity and enhanced FLT-3 inhibition.